Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting
21 mai 2020 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
12 mai 2020 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12
28 avr. 2020 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
04 mars 2020 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4
24 févr. 2020 16h01 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
02 janv. 2020 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
12 déc. 2019 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12
05 nov. 2019 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose
10 oct. 2019 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...